Redistributed manufacturing in healthcare: Creating new value through disruptive innovation

The RiHN White Paper is the first serious attempt to gather expertise and to explore applications in promising areas of healthcare that could benefit from RDM and covers early-stage user needs, challenges and priorities. The UK has an opportunity to lead in this area and RiHN has identified an extensive number of areas for fruitful R&D, crossing production technology, infrastructure, business and organisations. The paper serves as a foundation for discussing future technological roadmaps and engaging the wider community and stakeholders, as well as policy makers, in addressing the potential impact of RDM.The RiHN White Paper is of particular value to policy makers and funders seeking to specify action and to direct attention where it is needed. The White Paper is also useful for the research community, to support their proposals with credible research propositions and to show where collaboration with industry and the public sector will deliver the most benefits.In order to seize the opportunities presented by RDM RiHN proposes a bold new agenda that incorporates a whole healthcare system view of future implementation pathways and wider transformation implications. The priority areas for Future R&D can be summarised as follows: throughAutomated production platform technologies and supporting manufacturing infrastructuresAdvances in analytics and metrologyNew regulatory frameworks and governance pathwaysNew frameworks for business model and organisational transformationThe time to take action is now. Technologies are developing that have the potential to disrupt traditional healthcare pathways and offer therapies tailored to individual needs and physiological characteristics. The challenge is seizing this opportunity and make the UK a world leader in RDM

RiHN Fina Report PDF 2023

Over a period of two years, the EPSRC funded RiHN brought together a multi-disciplinary network of academics stakeholder organisations, clinical groups and industry to provide a forum to define the challenges of realising Redistributed Manufacturing (RDM) in deployed medical care In doing so the RiHN delivered the following outcomes14 PUBLICATIONS spanning Business and Management, Pharmacy, Dentistry, Additive manufacturing, Materials and Manufacturing Engineering£9M FURTHER FUNDING awarded to RIHN team, RiHN feasibility studies, RiHN Co-Is (47 ENGAGEMENT ACTIVITIES – Keynotes, workshops, conferences, podcasts, blogs, TV broadcasts, newspaper articles, working groupsINFLUENCE ON POLICY AND PRACTICE – MHRA POC regulation; Department of International Trade, Global Supply Chains Directorate; Westminster Health ForumRiHN FINAL REPORT – Redistributed Manufacturing in Healthcare: Transforming Deployed Medical CareThe strength of this report is that it combines key stakeholder expertise from a range of diverse backgrounds, enabling a multi-disciplinary perspective of the future of RDM in deployed healthcare. In order to seize the opportunities presented by RDM, RiHN proposes a bold new agenda that incorporates a whole system’s view of future implementation pathways and wider transformation implications. We are keen to hear your thoughts.. The time to take action is now. Implementing the opportunities proffered by RDM will be key in ensuring the future transformation of deployed medical care